Therapeutic inertia

Therapeutic inertia (also known as clinical inertia[1]) is a measurement of the resistance to therapeutic treatment for an existing medical condition. It is commonly measured as a percentage of the number of encounters in which a patient with a condition received new or increased therapeutic treatment out of the total number of visits to a health care professional by the patient. A high percentage indicates that the health care provider is slow to treat a medical condition. A low percentage indicates that a provider is extremely quick in prescribing new treatment at the onset of any medical condition.

Calculation

There are two common methods used in calculating therapeutic inertia. For the following examples, consider that a patient has five visits with a health provider. In four of those visits, a condition is not controlled (such as high blood pressure or high cholesterol). In two of those visits, the provider made a change to the patient's treatment for the condition.

In Dr. Okonofua's original paper, this patient's therapeutic inertia is calculated as where h is the number of visits with an uncontrolled condition, c is the number of visits in which a change was made, and v is the total number of visits.[2] Therefore, the patient's therapeutic inertia is .

An alternative, which avoids consideration of visits where the condition was already controlled and the provider should not be expected to make a treatment change, is . Using the above example, there are 2 changes and 4 visits with an uncontrolled condition. The therapeutic inertia is .

Reception

Therapeutic inertia was devised as a metric for measuring treatment of hypertension. It has now become a standard metric for analysing treatment of many common comorbidities such as diabetes[3] and hyperlipidemia.[4] Both feedback reporting processes and intervention studies aimed at reducing therapeutic inertia have been shown to increase control of hypertension,[5] diabetes, and hyperlipidemia.

References

  1. ↑ Reach, Gérard (2014-09-12), "To Do or Not to Do: A Critique of Medical Reason medical reason", Clinical Inertia, Cham: Springer International Publishing, pp. 73–95, ISBN 978-3-319-09881-4, retrieved 2020-12-19
  2. ↑ Eni C. Okonofua; Kit N. Simpson; Ammar Jesri; Shakaib U. Rehman; Valerie L. Durkalski; Brent M. Egan (January 23, 2006). "Therapeutic Inertia Is an Impediment to Achieving the Healthy People 2010 Blood Pressure Control Goals". Hypertension. 47 (2006, 47:345): 345–51. doi:10.1161/01.HYP.0000200702.76436.4b. PMID 16432045.
  3. ↑ Diabetes care: therapeutic inertia in doctors and patients
  4. ↑ Getting Patients to Their Lipid Targets: A Practical Approach to Implementing Therapeutic Lifestyle Changes
  5. ↑ Is blood pressure control to less than 140/less than 90 mmHg in 50% of all hypertensive patients as good as we can do in the USA: or is this as good as it gets?
  • OQUIN: The OQUIN:Hypertension Initiative at MUSC performed the initial study and reporting on therapeutic inertia.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.